Megadalton joins Waters' Immerse Cambridge labs
Megadalton Solutions has expanded its collaboration with Waters to bring its charge detection mass spectrometry technology to a broader set of biopharma customers by joining Waters' Immerse Cambridge lab.
Umoja Biopharma to develop in vivo immunotherapy platform
Umoja Biopharma has completed $53 million in series A financing to support development of its in vivo immunotherapy platform.
Obsidian, MD Anderson partner on solid tumor cell therapy
Obsidian Therapeutics and the University of Texas MD Anderson Cancer Center have entered a multiyear strategic collaboration for the research and development of novel engineered tumor infiltrating lymphocytes for the treatment of solid tumors.
Vivet, Pfizer to begin Wilson's disease gene therapy trial
The U.S. Food and Drug Administration (FDA) has cleared Vivet Therapeutics' investigational new drug application for the Gateway study, a phase I/II study evaluating Vivet's VTX-801, a proprietary, investigational gene therapy for the treatment of Wilson's disease.
Caribou inks deal with MSK to make allogeneic therapies
Memorial Sloan Kettering Cancer Center (MSK) has agreed to exclusively license its antibody fragments to CRISPR genome editing firm Caribou Biosciences to develop allogeneic cell therapies for cancer.
Precigen doses first patients with UltraCAR-T cells
Precigen said that the first patients in two phase I clinical trials have been treated with UltraCAR-T cells manufactured by its UltraPorator system.
LifeEdit Therapeutics joins ElevateBio's gene editing portfolio
Cell and gene therapy accelerator ElevateBio has added LifeEdit Therapeutics to the company's portfolio of therapeutic, technology, and manufacturing firms.
Factor Bioscience defends gene editing patent
The Russian Patent Office has denied a request by Advanced Gene and Cell Technologies to invalidate Factor Bioscience's patent (No. 2,691,027), which covers gene edited hematopoietic cells made using messenger RNA.
Bone Therapeutics acquires Catalent cell therapy manufacturer
Catalent Pharma Solutions has completed the acquisition of Bone Therapeutics' manufacturing subsidiary, Skeletal Cell Therapy Support.
Aruvant receives EMA orphan designation for sickle cell gene therapy
Aruvant has been granted orphan drug designation for ARU-1801, an investigational lentiviral gene therapy by the European Medicines Agency (EMA).
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter